KM501 for people with advanced HER2-positive solid cancers
Part of Cancer clinical trials.
This early-phase study tests KM501, a treatment targeting HER2, in adults with solid cancers that have worsened and for which standard treatment isn’t available or not tolerated. The goal is to see whether KM501 is safe and whether it can shrink or control the cancer in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign informed consent and be 18 to under 75 years old
- Your cancer must be an advanced solid tumor that has progressed, with no good standard options
- Your tumor must be HER2-positive or have a HER2 mutation, based on prior testing or a provided tissue sample
- Your health status must be good enough to participate (ECOG 0 or 1)
- You need measurable tumor spots (depending on cancer type) and an expected survival of at least 12 weeks
- You must meet key blood, liver, and kidney lab thresholds and be able to use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KH801 for people with advanced solid tumors (cancers that have spread) that haven't been helped by other treatments. The goal is to see if it is safe and how well it works.
This Phase 1 trial studies how a new medicine (KC1036) works and how safe it is for people with advanced solid cancers that have grown despite standard treatments. It may help future patients by showing whether the drug can control cancer in difficult-to-treat cases.
This early-stage study tests KM257, a new cancer treatment, in people with advanced solid tumors that are HER2-positive or HER2-expressing. The goal is to see how well it can work and how safe it is.
This Phase 1 trial tests KM602, a new study treatment, in people with advanced solid tumors like melanoma or non-small cell lung cancer that have progressed after standard treatments. If you qualify, the goal is to see how the drug works and how safe it is in early research.
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.